| Deferred income |
27. Deferred income The movement in the non-current and current deferred income is detailed in the table below. | | | | | | | | | | | | | | | Gilead collaboration
agreement
for filgotinib | | Gilead collaboration
agreement
for drug
discovery platform (1) | | Other
deferred income | | Total | | | | (Euro, in thousands) | | | | | | | | | | | | | | On January 1, 2023 | | € | 456,352 | | € | 1,529,405 | | € | 3,474 | | | 1,989,230 | Of which current portion: | | | 133,470 | | | 230,022 | | | 2,139 | | | 365,631 | | | | | | | | | | | | | | Reclassification to liabilities directly associated with assets in disposal group classified as held for sale | | | | | | | | | (60) | | | (60) | Significant financing component (2) | | | (645) | | | | | | | | | (645) | | | | | | | | | | | | | | Revenue recognition of upfront | | | (361,412) | | | (230,242) | | | | | | (591,654) | Revenue recognition of milestones | | | (68,027) | | | | | | | | | (68,027) | | | | | | | | | | | | | | Other movements | | | | | | | | | (1,382) | | | (1,382) | | | | | | | | | | | | | | On December 31, 2023 | | € | 26,268 | | € | 1,299,163 | | € | 2,032 | | € | 1,327,463 | Of which current portion: | | | 25,054 | | | 230,070 | | | 1,146 | | | 256,270 | | | | | | | | | | | | | | Significant financing component (2) | | | (227) | | | | | | | | | (227) | | | | | | | | | | | | | | Revenue recognition of upfront | | | (21,952) | | | (230,182) | | | | | | (252,134) | Revenue recognition of milestones | | | (4,089) | | | | | | | | | (4,089) | | | | | | | | | | | | | | Other movements | | | | | | | | | 339 | | | 339 | | | | | | | | | | | | | | On December 31, 2024 | | € | — | | € | 1,068,981 | | € | 2,371 | | € | 1,071,352 | Of which current portion: | | | — | | | 230,105 | | | 2,371 | | | 232,476 |
| (1) | The upfront received and the outstanding balance comprise the issuance liabilities for the warrants and the upfront payment allocated to the drug discovery platform. |
| (2) | With regard to the additional consideration received for the extended cost sharing for filgotinib, we assume the existence of a significant financing component reflecting the time value of money on the estimated recognition period |
We refer to note 2 for a detail of the allocation of the transaction price of our collaboration with Gilead and to note 5 and note 7 for a description of our revenue recognition. |